Klaas Heinemann

Managing Director

Klaas Heinemann is a physician and epidemiologist who has headed ZEG Berlin since 2009 and sits on the Kantar Health Europe management board. The principal investigator for many studies, Klaas provides strategic direction as ZEG-Berlin diversifies beyond women’s health studies to bring its data methodology to other realms of health.

Klaas trained in internal medicine at Charite University Hospital, Berlin before completing postgraduate masters degrees in business and administration (Berlin School of Economics, Berlin), and epidemiology (London School of Hygiene and Tropical Medicine, London). Prior to his appointment as managing director, Klaas was an external consultant for ZEG Berlin. Previously he worked in the US and Germany as a Medical Expert in Global Medical Affairs at Schering AG and later Bayer Pharma, planning and managing clinical research focusing on Phase III clinical studies and post-market phase IV study design.

Publications

Barnett Clare, Bauerfeind Anja, von Stockum Sophia, Heinemann Klaas, Thromboembolic safety of norethisterone vs levonorgestrel in combined oral contraceptive users: a pooled analysis of 4 large prospective cohort studies AJOG Global Report. 2022; 10.1016/j.xagr.2021.100041.

Boehnke Tanja, Bauerfeind Anja, Hagemann Christine, Lange Jens A., Heinemann Klaas, Intrauterine device prescribing patterns and types in Europe – a cross-sectional analysis of the European Active Surveillance LCS12 Study. European Gynecology & Obstetrics. 2022; 29–40. 10.53260/EGO.224015 .
Download PDF: Boehnke-et-al.-2022_IUD-prescribing-patterns-and-types-in-Europe_LCS12.pdf

Reed Suzanne, Do Minh Thai, Lange Jens A., Koro Carol, Heinemann Klaas, Pregnancy and pregnancy outcomes in a prospective cohort study: Final Results from the Nexplanon Observational Risk Assessment Study (NORA) Contraception. 2022; 10.1016/j.contraception.2022.109920.

Moehner Sabine, Becker Kerstin, Lange Jens A., von Stockum Sophia, Serrani Marco, Heinemann Klaas, Long-term treatment of endometriosis with dienogest: Real-world results from the VIPOS study Journal of Endometriosis and Pelvic Pain Disorders. 2021; 10.1177/2284026521993688.

Barnett Clare, Bauerfeind Anja, von Stockum Sophia, Heinemann Klaas, Thromboembolic safety profile of low-dose estradiol (valerate) in combined hormonal preparations: Implications for the development of new hormonal endometriosis and uterine fibroid therapies Journal of Endometriosis and Pelvic Pain Disorders. 2021; 1 - 10. 10.1177/22840265211019546.

Reed Suzanne, Koro Carol, DiBello Julia, Becker Kerstin, Bauerfeind Anja, Franke Christian, Heinemann Klaas, Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism European Journal of Contraception & Reproductive Health Care. 2021; 1 - 8. 10.1080/13625187.2021.1987410 .

Reed Suzanne, Koro Carol, DiBello Julia, Becker Kerstin, Bauerfeind Anja, Franke Christian, Heinemann Klaas, Unintended pregnancy in users of nomegestrol acetate and 17β-oestradiol (NOMAC-E2) compared with levonorgestrel-containing combined oral contraceptives: final results from the PRO-E2 study European Journal of Contraception & Reproductive Health Care. 2021; 1-7. 10.1080/13625187.2021.1988923.

Becker Kerstin, Heinemann Klaas, Imthurn Bruno, Marions Lena, Moehner Sabine, Gerlinger Christoph, Serrani Marco, Faustmann Thomas, Real world data on symptomology and diagnostic approaches of 27,840 women living with endometriosis. Scientific Reports. 2021; 10.1038/s41598-021-99681-3.

Heinemann Klaas, Imthurn Bruno, Marions Lena, Gerlinger Christoph, Becker Kerstin, Moehner Sabine, Faustmann Thomas, Safety of Dienogest and Other Hormonal Treatments for Endometriosis in Real-World Clinical Practice (VIPOS): A Large Noninterventional Study Advances in Therapy. 2020; 2528-2537. 10.1007/s12325-020-01331-z.

Moehner Sabine, Becker Kerstin, Lange Jens A., von Stockum Sophia, Heinemann Klaas, Risk of depression and anemia in users of hormonal endometriosis treatments: Results from the VIPOS study European Journal of Obstetrics &Gynecology and Reproductive Biology. 2020; 212 - 217. 10.1016/j.ejogrb.2020.05.049.

Dinger Jürgen, Heinemann Klaas, Moehner Sabine, Combined oral contraceptives containing dienogest and estradiol valerate may carry a lower risk of venous and arterial thromboembolism compared to conventional preparations: Results from the extended INAS-SCORE study. Frontiers in Women's Health. 2020; Vol. 5: 1-8. 10.15761/FWH.1000178.
Download PDF: Jürgen-et-al.-2020_Results-from-the-extended-INAS-SCORE-study.pdf

Barnett Clare, Bauerfeind Anja, von Stockum Sophia, Grimes David A., Heinemann Klaas, Comparing the Cardiovascular Risk of Norethindrone Acetate & Levonorgestrel Pills: Is There a Difference? [10I]. Obstetrics & Gynecology. 2020; Volume 135 - Issue - p 94S. 10.1097/01.AOG.0000664136.96902.7e.

Reed Suzanne, Do Minh Thai, Lange Jens A., Koro Carol, Fox Michelle, Heinemann Klaas, Real world data on Nexplanon® procedure-related events: final results from the Nexplanon observational risk assessment study (NORA) Contraception. 2019; pii: S0010-7824(19)30131-3. 10.1016/j.contraception.2019.03.052.

Barnett Clare, Dinger Jürgen, Do Minh Thai, Heinemann Klaas, Unintended pregnancy rates differ according to combined oral contraceptive – results from the INAS-SCORE study Contraception & Reproductive Health Care. 2019; 1-4. 10.1080/13625187.2019.1629412.

Barnett Clare, Moehner Sabine, Do Minh Thai, Heinemann Klaas, Perforation risk and intra-uterine devices: results of the EURAS-IUD 5-year extension study The European Journal of Contraception and Reproductive Health Care. 2018; page 1-5.

Heinemann Klaas, Barnett Clare, Reed Suzanne, Moehner Sabine, Do Minh Thai, IUD use among parous women and risk of uterine perforation: a secondary analysis Contraception. 2017; Volume 95, Issue 6, Pages 605–607.

Heinemann Klaas, Pauls Karl, Drug Utilization Study on the Prescribing Indications for CPA/EE (Cyproterone acetate 2mg in combination with Ethinylestradiol 35mcg) in 5 European Countries Pharmacoepidemiology and Drug Safety. 2017; Volume 26, Issue S2, Pages 1-674.

Heinemann Klaas, Safety and efficacy of intrauterine devices: Baseline characteristics of 32,022 study participants from the EURAS-LCS12 study Pharmacoepidemiology and Drug Safety. 2017; Volume 26, Issue Supplement S2 Pages 1–674.

Bauerfeind Anja, Do Minh Thai, Heinemann Klaas, The Influence of Women’s Educational Level on Unintended Pregnancy Rates amongst Users of Combined Oral Contraceptives Pharmacoepidemiology and Drug Safety. 2017; Volume 26, Issue Supplement S2 Pages 1–674.

Heinemann Klaas, Dinger Jürgen, Do Minh Thai, Franke Christian, Unintended Pregnancies in Users of Different Combined Oral Contraceptives – Final results from the INAS-SCORE Study Pharmacoepidemiology and Drug Safety. 2017; Volume 26, Issue Supplement S2 Pages 1–674.

Heinemann Klaas, Hagemann Christine, Do Minh Thai, Franke Christian, Dinger Jürgen, Cardiovascular Safety in Users of Different Combined Oral Contraceptives – Final results from the INAS-SCORE Study Pharmacoepidemiology and Drug Safety. 2017; Volume 26, Issue Supplement S2 Pages 1–674.

Barnett Clare, Hagemann Christine, Dinger Jürgen, Do Minh Thai, Heinemann Klaas, Fertility and combined oral contraceptives - unintended pregnancies and planned pregnancies following oral contraceptive use - results from the INAS-SCORE study Eur J Contracept Reprod health Care. 2016; Oct 17:1-7. 10.1080/13625187.2016.1241991.

Dinger Jürgen, Do Minh Thai, Heinemann Klaas, Impact of Estrogen Type on Cardiovascular Safety of Combined Oral Contraceptives Contraception. 2016; Oct;94(4):328-39. 10.1016/j.contraception.2016.06.010.

Heinemann Klaas, Moehner Sabine, Do Minh Thai, Reed Suzanne, Intrauterine Devices and the Risk of Uterine Perforations: Final Results from the EURAS-IUD 5-years study Pharmacoepidemiology and Drug Safety. 2016; Aug;25:(S3):3-680. 10.1002/pds.4070.

Heinemann Klaas, Moehner Sabine, Reed Suzanne, Do Minh Thai, Unwanted pregnancies in women using Intrauterine Devices: final results from the EURAS-IUD 5-years study Pharmacoepidemiology and Drug Safety. 2016; Aug;25:(S3):3-680. 10.1002/pds.4070.

Barnett Clare, Bauerfeind Anja, Do Minh Thai, Heinemann Klaas, Influence of age and BMI on risk of venous thromboembolism: a meta-analysis of 246,513 women using combined oral contraceptives based on 521,516 women-years. Pharmacoepidemiology and Drug Safety. 2016; Aug;25:(S3):3-680. 10.1002/pds.4070.

Bauerfeind Anja, Barnett Clare, Do Minh Thai, Heinemann Klaas, The effect of BMI on unintended pregnancy rates amongst users of combined oral contraceptives Pharmacoepidemiology and Drug Safety. 2016; Aug;25:(S3):3-680. 10.1002/pds.4070.

Bardenheuer Kristina, Heinemann Klaas, Do Minh Thai, Franke Christian, Cardiovascular Safety in Users of Different Combined Oral Contraceptives - Final Results from the INAS-SCORE study Pharmac. 2015; (24) S1, 1–587. 10.1002/pds.3838.

Heinemann Klaas, Reed Suzanne, Moehner Sabine, Do Minh Thai, Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. Contraception. 2015; Apr;91(4):280-3. 10.1016/j.contraception.2015.01.011.

Heinemann Klaas, Reed Suzanne, Moehner Sabine, Do Minh Thai, Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices. Contraception. 2015; 10.1016/j.contraception.2015.01.007.

Heinemann Klaas, Dinger Jürgen, Baseline risk factors for cardiovascular events: differences between the USA and Russia in a study population of combined oral contraceptives Pharmacoepidemiology and Drug Safety. 2014; Sep; 23(S1): 1-497. 10.1002/pds.3701.

Dinger Jürgen, Bardenheuer Kristina, Heinemann Klaas, Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Contraception. 2014; Apr; 89(4): 253–63.. 10.1016/j.contraception.2014.01.023.

Heinemann Klaas, Breastfeeding as as risk factor for uterine preforation during IUD insertion: interim results from the ERUAS-IUD study Pharmacoepidemiology and Drug Safety. 2013; 22(S1) 1-521. 10.1002/pds.3512.

Dinger Jürgen, Heinemann Klaas, Transatlantic active surveillance of cardiovascular safety (TASC) of an Etonogestrel/Ethinylestradiol-containing vaginal ring. Pharmacoepidemiology and Drug Safety. 2013; 22(S1) 1-521. 10.1002/pds.3512.

Heinemann Klaas, Dinger Jürgen, Bardenheuer Kristina, The safety of oral contraceptives in adolescents. Pharmacoepidemiology and Drug Safety. 2013; 22(S1) 1-521. 10.1002/pds.3512.

Heinemann Klaas, Ectopic pregnancies under IUD use: interim results from the EURAS-IUD study Pharmacoepidemiology and Drug Safety. 2013; 22(S1) 1-521. 10.1002/pds.3512.

Dinger Jürgen, Heinemann Klaas, Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. Obstetrics & Gynecology. 2013; 122(4): 800 - 808. 10.1097/AOG.0b013e3182a5ec6b.
Download PDF: Cardiovascular_Risk_Associated_With_the_Use_of_an.11.pdf

Barnett Clare, Heinemann Klaas, Dinger Jürgen, Intrauterine devices and risk of uterine perforations: interim results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2012; Aug; 21(S2) 45. DOI 10.1002.

Heinemann Klaas, Assmann Anita, Long term active surveillance study for oral contraceptives (LASS): final results on cardiovascular safety. Pharmacoepidemiology and Drug Safety. 2012; Aug; 21(S3) 360. DOI 10.1002.

Heinemann Klaas, Assmann Anita, Dinger Jürgen, The safety of oral hormone replacement therapy: final results from the EURAS-HRT study. Pharmacoepidemiology and Drug Safety. 2012; Aug; 21(S3) 365. DOI 10.1002.

Dennerstein L, Lehert P, Heinemann Klaas, Epidemiology of premenstrual symptoms and disorders. Menopause International. 2012; Jun;18(2):48-51.

Heinemann Lothar A , Do Minh Thai, Heinemann Klaas, Lindemann M , Filonenko A, Intercountry assessment of the impact of severe premenstrual disorders on work and daily activities. Health Care Women International. 2012; Feb;33(2):109-24.

Heinemann Klaas, Heinemann Lothar A , Comparative risks of venous thromboembolism among users of oral contraceptives containing drospirenone and levonorgestrel.. J Fam Plann Reprod Health Care. 2011; Jul;37(3):132-5. 10.1136/jfprhc-2011-14524.

Barnett Clare, Heinemann Klaas, Dinger Jürgen, Complications associated with unintended pregnancies under IUD use: results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 125.

Heinemann Klaas, EURAS-HRT: study design and baseline characteristics - international menopause society. The Journal of Adult Women`s Health & Medicine. 2011; Vol. 14 Supplement 1: 214.

Barnett Clare, Heinemann Klaas, Dinger Jürgen, Intrauterine devices and the risk of uterine perforation: interim results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 233.

Heinemann Klaas, Barnett Clare, Dinger Jürgen, Risk factors for uterine perforations during IUD insertion: interim results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 138.

Assmann Anita, Heinemann Klaas, Dinger Jürgen, The safety of oral hormone replacement therapy: final results from the EURAS-HRT study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 181.

Dennerstein L, Lehert P, Heinemann Klaas, Global epidemiological study of variation of premenstrual symptoms with age and sociodemographic factors. Menopause International. 2011; Sep: 17(3):96-101. 10.1258/mi.2011.011028.

Dennerstein L, Lehert P, Heinemann Klaas, Global study of women's experiences of premenstrual symptoms and their effects on daily life. Menopause International. 2011; Sep: 17(3):88-95. 10.1258/mi.2011.011027.

Assmann Anita, Heinemann Klaas, Dinger Jürgen, The safety of oral hormone replacement therapy: Interim results from the EURAS-HRT study. Pharmacoepidemiology and Drug Safety. 2010; 19:S31-32.

Heinemann Klaas, Problems associated with comprehensive detection/validation of unexpected ADRs in a population. PRM Newsletter. 2010; Apr 2010;5:1-3,9-1.

Dennerstein L, Lehert P, Bäckström T, Heinemann Klaas, The effect of premenstrual symptoms on activities of daily life. Fertil Steril. 2010; Aug;94(3):1059-64.. 10.1016/j.fertnstert.2009.04.023.

Bardenheuer Kristina, Dinger Jürgen, Assmann Anita, Heinemann Klaas, Leddin Janko, Drug utilization study on the prescribing indications of oral contraceptives in croatia. Pharmacoepidemiology and Drug Safety. 2010; 19:S55.

Dennerstein L, Lehert P, Bäckström T, Heinemann Klaas, Premenstrual symptoms - severity, duration and typology: an international cross-sectional study Menopause International. 2009; Sep;15(3):120-6. 10.1258/mi.2009.009030.

Bäckström T, Heinemann Klaas, Nyberg S, Hammarbäck S, Definition and prevalence of premenstrual syndromes. Gynaecology Forum. 2009; 14(3).

Heinemann Klaas, Rübig A, Strothmann A, Nahum GG, Heinemann Lothar A , Prevalence and opinions of hormone therapy prior to the Women’s Health Initiative: a multinational survey in four continents. J Women’s Health. 2008; 17:1-16.

Heinemann Klaas, Saad F, Wiesemes M, Heinemann Lothar A , Expectations towards a novel MFC and potential user types. Results of a multinational survey. J Andrology. 2005; 26(2): 155-62.

Heinemann Klaas, Saad F, Wiesemes M, Heinemann Lothar A , Attitudes toward male fertility control; a multinational survey in four continents. Human Reproduction. 2005; 20 (2): 549-56.

Heinemann Lothar A , Potthoff P, Heinemann Klaas, Pauls Alfred, Ahlers C J, Saad F, Scale for Quality of Sexual Function (QSF) as an outcome measure for both genders?. J Sex Med. 2005; 2:82-95.

Heinemann Lothar A , Saad F, Heinemann Klaas, Do Minh Thai, Can results of the AMS scale predict those of screening scales for androgen deficiency?. Aging Male. 2004; 7:211-18.

Heinemann Klaas, Alexander Ruebig Alexander, Potthoff P, Schneider HPG, Strelow Frank, Heinemann Lothar A , Do Minh Thai, The Menopause Rating Scale: A methodological review. Health and Quality of Life Outcomes. 2004; 2:45 (2 September 2004). 10.1186/1477-7525-2-45.

Heinemann Klaas, Thiel C, Lewis Michael, Raff T, Heinemann Lothar A , Benign gynecological tumors: estimated incidence. Results of the German Cohort study on Women’s Health Eur J Obst Gyn Reprod Biol. 2003; 107: 78-80.

Heinemann Klaas, Saad F, Sweating attacks: key symptom in menopausal transition only for women? Eur Urol. 2003;

Heinemann Klaas, Assmann Anita, Lewis Michael, Garbe E, Heinemann Lothar A , Teichmann A T, Trend der HRT Nutzung in Deutschland 1980-1999. Ergebnisse der Deutschen Kohortenstudie zur Frauengesundheit. 2002; 43:508-511.

Heinemann Klaas, Lewis Michael, Assmann Anita, Garbe E, Heinemann Lothar A , Trend der OC-Nutzung in einer Deutschen Frauen-Kohorte 1980-1999 Zentralbl Gynakol. 2002; 124(2): 128-131. DOI: 10.1055/s-2002-24241.

Heinemann Klaas, Heinemann Lothar A , Assmann Anita, Schneider HPG, Reliabilität der Menopause-Rating-Skala (MRS). Untersuchung für die Deutsche Bevölkerung Zentralbl Gynakol. 2002; 124(3): 161-163. DOI: 10.1055/s-2002-32268.

Heinemann Lothar A , Assmann Anita, Heinemann Klaas, Use of oral contraceptives containing dienogest and risk of venous thromboembolism; an extended summary report. Life and Medical Science Online. 2001; 2.

Potthoff P, Heinemann Klaas, Schneider HPG, osemeier HP, Hauser G A, Menopause-Rating Skala (MRS II): Methodische Standardisierung in der deutschen Bevoelkerung Zentralbl Gynakol. 2000; 122(5):280-6..

Heinemann Klaas, Heinemann Lothar A , Do Minh Thai, Möhner M, Heuchert G E, Occupational exposure and liver cancer in women: results of the Multicentre International Liver Tumour Study (MILTS). Occup Med (Lond). 2000; Aug;50(6):422-9.

Managing Director

Publications

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Expertise

Services

ENCePP

General Data Protection Regulation

Managing Director

Publications

Footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Expertise

Services

ENCePP

General Data Protection Regulation